Cancer Loyalty Card Study (CLOCS): protocol for an observational case-control study focusing on the patient interval in ovarian cancer diagnosis

Hannah R Brewer, Yasemin Hirst, Sudha Sundar, Marc Chadeau-Hyam, James M Flanagan, Hannah R Brewer, Yasemin Hirst, Sudha Sundar, Marc Chadeau-Hyam, James M Flanagan

Abstract

Introduction: Ovarian cancer is the eighth most common cancer in women worldwide, and about 1 in 5 women with ovarian cancer do not receive treatment, because they are too unwell by the time they are diagnosed. Symptoms of ovarian cancer are non-specific or can be associated with other common conditions, and women experiencing these symptoms have been shown to self-manage them using over-the-counter medication. Results from a recent proof-of-concept study suggest there may be an increase in the purchases of painkillers and indigestion medication 10-12 months before ovarian cancer diagnosis. We propose a case-control study, as part of a larger project called the Cancer Loyalty Card Study (CLOCS), to investigate whether a significant change in medication purchases could be an indication for early signs of ovarian cancer, using data already collected through store loyalty cards.

Methods and analysis: Using a retrospective case-control design, we aim to recruit 500 women diagnosed with ovarian cancer (cases) and 500 women without ovarian cancer (controls) in the UK who hold a loyalty card with at least one participating high street retailer. We will use pre-existing loyalty card data to compare past purchase patterns of cases with those of controls. In order to assess ovarian cancer risk in participants and their purchase patterns, we will collect information from participants on ovarian cancer risk factors and clinical data including symptoms experienced before diagnosis from recruited women with ovarian cancer.

Ethics and dissemination: CLOCS was reviewed and approved by the North West-Greater Manchester South Research Ethics Committee (19/NW/0427). Study outcomes will be disseminated through academic publications, the study website, social media and a report to the research sites that support the study once results are published.

Trial registration number: ISRCTN 14897082, CPMS 43323, NCT03994653.

Keywords: epidemiology; gynaecological oncology; oncology; public health.

Conflict of interest statement

Competing interests: None declared.

© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY. Published by BMJ.

Figures

Figure 1
Figure 1
Pathway to diagnosis highlighting the patient interval that Cancer Loyalty Card Study (CLOCS) will investigate. GP, general practitioner.
Figure 2
Figure 2
Cancer Loyalty Card Study (CLOCS) recruitment process.
Figure 3
Figure 3
Cancer Loyalty Card Study (CLOCS) data flow chart.

References

    1. Cancer Research UK Ovarian cancer statistics. Available: [Accessed 9 Apr 2019].
    1. Funston G, Van Melle M, Baun M-LL, et al. . Variation in the initial assessment and investigation for ovarian cancer in symptomatic women: a systematic review of international guidelines. BMC Cancer 2019;19:1028. 10.1186/s12885-019-6211-2
    1. National Institute for Health and Care Excellence Ovarian cancer: recognition and initial management. Clinical guideline [CG122], 2011.
    1. Ebell MH, Culp MB, Radke TJ. A systematic review of symptoms for the diagnosis of ovarian cancer. Am J Prev Med 2016;50:384–94. 10.1016/j.amepre.2015.09.023
    1. Goff B. Symptoms associated with ovarian cancer. Clin Obstet Gynecol 2012;55:36–42. 10.1097/GRF.0b013e3182480523
    1. Hamilton W, Peters TJ, Bankhead C, et al. . Risk of ovarian cancer in women with symptoms in primary care: population based case-control study. BMJ 2009;339:b2998. 10.1136/bmj.b2998
    1. Brain KE, Smits S, Simon AE, et al. . Ovarian cancer symptom awareness and anticipated delayed presentation in a population sample. BMC Cancer 2014;14:171. 10.1186/1471-2407-14-171
    1. Low EL, Waller J, Menon U, et al. . Ovarian cancer symptom awareness and anticipated time to help-seeking for symptoms among UK women. J Fam Plann Reprod Health Care 2013;39:163–71. 10.1136/jfprhc-2012-100473
    1. ICBP The International cancer benchmarking partnership evidence for policy and practice October 2016, 2016.
    1. Low EL, Whitaker KL, Simon AE, et al. . Women's interpretation of and responses to potential gynaecological cancer symptoms: a qualitative interview study. BMJ Open 2015;5:e008082. 10.1136/bmjopen-2015-008082
    1. Whitaker KL, Winstanley K, Macleod U, et al. . Low cancer suspicion following experience of a cancer 'warning sign'. Eur J Cancer 2015;51:2473–9. 10.1016/j.ejca.2015.07.014
    1. Jayde V, Boughton M. The diagnostic journey of ovarian cancer: A review of the literature and suggestions for practice. Contemporary nurse, 2012.
    1. Gilbert L, Basso O, Sampalis J, et al. . Assessment of symptomatic women for early diagnosis of ovarian cancer: results from the prospective dove pilot project. Lancet Oncol 2012;13:285–91. 10.1016/S1470-2045(11)70333-3
    1. Flanagan JM, Skrobanski H, Shi X, et al. . Self-Care behaviors of ovarian cancer patients before their diagnosis: proof-of-concept study. JMIR Cancer 2019;5:e10447. 10.2196/10447
    1. Reid BM, Permuth JB, Sellers TA. Epidemiology of ovarian cancer: a review. Cancer Biol Med 2017;14:9–32. 10.20892/j.issn.2095-3941.2016.0084
    1. Office for National Statistics Ethnic group, National identity and religion, measuring equality: a guide for the collection and classification of ethnic group, national identity and religion data in the UK, 2016. Available:
    1. Clyde MA, Palmieri Weber R, Iversen ES, et al. . Risk prediction for epithelial ovarian cancer in 11 United States–Based case-control studies: incorporation of epidemiologic risk factors and 17 confirmed genetic loci. Am J Epidemiol 2016;184:555–69. 10.1093/aje/kww091
    1. Meisel SF, Side L, Fraser L, et al. . Population-based, risk-stratified genetic testing for ovarian cancer risk: a focus group study. Public Health Genomics 2013;16:184–91. 10.1159/000352028
    1. Minlikeeva AN, Freudenheim JL, Eng KH, et al. . History of comorbidities and survival of ovarian cancer patients, results from the ovarian cancer association Consortium. Cancer Epidemiol Biomarkers Prev 2017;26:1470–3. 10.1158/1055-9965.EPI-17-0367
    1. von Elm E, Altman DG, Egger M, et al. . The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet 2007;370:1453–7. 10.1016/S0140-6736(07)61602-X

Source: PubMed

3
Subskrybuj